A. Abbas and A. Lichtman, Cellular and molecular immunology, 2003.

J. Antoon, M. Bratton, L. Guillot, S. Wadsworth, V. Salvo et al., Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase, Am j cancer res, vol.2, issue.4, pp.446-458, 2012.

J. Askling, E. Baecklund, F. Granath, P. Geborek, M. Fored et al., Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register, Annals of the Rheumatic Diseases, vol.68, issue.5, pp.648-655, 2009.
DOI : 10.1136/ard.2007.085852

F. Balkwill, Tumour necrosis factor and cancer, Nature Reviews Cancer, vol.265, issue.5, pp.361-371, 2009.
DOI : 10.1038/nature01322

G. Bastida and B. Beltran, Ulcerative colitis in smokers, non-smokers and ex-smokers, World Journal of Gastroenterology, vol.17, issue.22, pp.2740-2747, 2011.
DOI : 10.3748/wjg.v17.i22.2740

G. Bouliane, N. Hozumi, and M. Schulman, Production of functional chimaeric mouse/human antibody, Nature, vol.103, issue.5995, pp.312-643, 1984.
DOI : 10.1128/MCB.2.9.1033

M. Breban, P. Ravaud, P. Claudepierre, G. Baron, Y. Henry et al., Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment, Arthritis & Rheumatism, vol.54, issue.1, pp.88-97, 2008.
DOI : 10.1016/S1521-6942(02)90245-7

URL : https://hal.archives-ouvertes.fr/hal-00496246

M. Buch, P. Conaghan, M. Quinn, S. Bingham, D. Veale et al., True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin ???, Annals of the Rheumatic Diseases, vol.63, issue.10, pp.1344-1346, 2004.
DOI : 10.1136/ard.2003.014878

M. Buch, A. Rubbert-roth, and G. Ferraccioli, To switch or not to switch after a poor response to a TNF?? blocker? It is not only a matter of ACR20 OR ACR50, Autoimmunity Reviews, vol.11, issue.8, pp.558-562, 2012.
DOI : 10.1016/j.autrev.2011.10.012

E. Campalani and J. Barker, The Clinical Genetics of Psoriasis, Current Genomics, vol.6, issue.1, pp.51-60, 2005.
DOI : 10.2174/1389202053202157

J. Carter, J. Valeriano, and F. Vasey, Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship?, J Rheumatol, vol.33, issue.5, pp.1014-1017, 2006.

L. Chatenoud and J. Bach, Immunologie (5ème édition) De la biologie à la clinique. Flammarion Médecine-sciences, p.416, 2008.

G. Cohen, N. Courvoisier, J. Cohen, S. Zaltni, J. Sany et al., The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis, Clin Exp Rheumatol, vol.23, issue.6, pp.795-800, 2005.

C. Des-universitaires-en-hepato-gastro-entérologie and C. , Item 118, 2009.

. Maladie-de-crohn-et-recocolite-hémorragique, Hepato-Gastro-Entérologie, pp.71-87

A. Finckh, J. Simard, C. Gabay, and P. Guerne, Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.65, issue.6, pp.746-752, 2006.
DOI : 10.1136/ard.2005.045062

S. Gangloff, Réaction inflammatoire. Immunologie 4 ème édition, Genetet N, 2002.

M. Gardam, E. Keystone, R. Menzies, S. Manners, E. Skamene et al., Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management, The Lancet Infectious Diseases, vol.3, issue.3, pp.148-155, 2003.
DOI : 10.1016/S1473-3099(03)00545-0

R. Goldsby, T. Kindt, and O. B. , IMMUNOLOGIE, le cours de janis Kuby. Dunod, pp.371-393, 2003.

M. He, A. Smith, J. Oslob, W. Flanagan, A. Braisted et al., Small-molecule inhibition of TNF-alpha, Science, issue.5750, pp.310-1022, 2005.

C. Laresche, S. Penz, F. Pelletier, F. Locatelli, F. Aubin et al., Efficacité de l'infliximab dans le traitement d'un psoriasis pustuleux généralisé induit par l'hydroxychloroquine. Annales de dermatologie et de vénérologie, pp.138-206, 2011.
DOI : 10.1016/j.annder.2011.10.201

J. Lawrence, Heberden Oration, 1969. Rheumatoid arthritis--nature or nurture?, Annals of the Rheumatic Diseases, vol.29, issue.4, pp.357-379, 1970.
DOI : 10.1136/ard.29.4.357

L. Jeunne and C. , Risques des médicaments anti-inflammatoires et immunosuppresseurs au cours de la grossesse. La Revue de médecine interne, pp.31-35, 2011.

A. Lobuglio, R. Wheeler, T. J. Hanes, A. Rogers, K. Harvey et al., Mouse/human chimeric monoclonal antibody in man: kinetics and immune response., Proceedings of the National Academy of Sciences, vol.86, issue.11, pp.86-4220, 1989.
DOI : 10.1073/pnas.86.11.4220

A. Mackey, L. Green, L. Liang, P. Dinndorf, and M. Avigan, Hepatosplenic T Cell Lymphoma Associated With Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.44, issue.2, pp.265-267, 2007.
DOI : 10.1097/MPG.0b013e31802f6424

U. Mahadevan, D. Wolf, M. Dubinsky, A. Cortot, S. Lee et al., Placental Transfer of Anti???Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.11, issue.3, pp.286-292, 2013.
DOI : 10.1016/j.cgh.2012.11.011

P. Martin, S. Oneda, and G. Treacy, Effects of an Anti-TNF-? Monoclonal Antibody, Administered Throughout Pregnancy and Lactation, on the Development of the Macaque Immune System, American Journal of Reproductive Immunology, vol.28, issue.2, pp.138-149, 2007.
DOI : 10.1016/j.cyto.2005.07.003

H. Marzo-ortega, D. Mcgonagle, O. Connor, P. , and E. P. , Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis, Annals of the Rheumatic Diseases, vol.62, issue.1, 2003.
DOI : 10.1136/ard.62.1.74

S. Mazumdar and G. D. , Golimumab, mAbs, vol.66, issue.5, pp.422-431, 2009.
DOI : 10.2165/00003495-200969050-00007

I. Mcinnes, A. Kavanaugh, A. Gottlieb, L. Puig, P. Rahman et al., Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial, The Lancet, vol.382, issue.9894, p.381, 2013.
DOI : 10.1016/S0140-6736(13)60594-2

P. Mease, Adalimumab in the treatment of arthritis, Therapeutics and Clinical Risk Management, vol.3, issue.1, pp.133-148, 2007.
DOI : 10.2147/tcrm.2007.3.1.133

P. Mease and P. Helliwell, atlas du rhumatisme psoriasique, p.122, 2009.

S. Miwataschi, Y. Arikawa, E. Kotani, M. Miyamoto, K. Naruo et al., -[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a Potent and Orally Active Anti-Rheumatoid Arthritis Agent, Journal of Medicinal Chemistry, vol.48, issue.19, pp.5966-5979, 2005.
DOI : 10.1021/jm050165o

A. Montalban, E. Boman, C. Chang, S. Ceide, R. Dahl et al., KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase, European Journal of Pharmacology, vol.632, issue.1-3, pp.1-3, 2010.
DOI : 10.1016/j.ejphar.2010.01.011

A. Morris, G. Fischer, M. Rogers, and W. K. , Childhood Psoriasis: A Clinical Review of 1262 Cases, Pediatric Dermatology, vol.20, issue.3, pp.188-198, 2001.
DOI : 10.1111/j.1365-4362.1981.tb00423.x

S. Morrison, M. Johnson, L. Herzenberg, and V. T. , Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains., Proceedings of the National Academy of Sciences, vol.81, issue.21, 1984.
DOI : 10.1073/pnas.81.21.6851

URL : http://www.pnas.org/content/81/21/6851.full.pdf

S. Mpofu, C. Estrach, J. Curtis, and R. Moots, Treatment of respiratory complications in recalcitrant relapsing polychondritis with infliximab, Rheumatology, vol.42, issue.9, pp.1117-1118, 2003.
DOI : 10.1093/rheumatology/keg280

T. Okoro, S. Tafazal, S. Longworth, and P. Sell, Tumor necrosis alpha-blocking agent (etanercept): a triple blind randomized controlled trial of its use in treatment of sciatica, 2010.

I. Olivieri, P. Leccese, A. Padula, D. Angelo, S. Nigro et al., Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab, Clin, 2011.

R. Palframan, M. Airey, A. Moore, A. Vugler, and A. Nesbit, Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis, Journal of Immunological Methods, vol.348, issue.1-2, pp.1-2, 2009.
DOI : 10.1016/j.jim.2009.06.009

K. Papp, Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis, Current Medical Research and Opinion, vol.26, issue.10, pp.2287-2300, 2010.
DOI : 10.1185/03007995.2010.507492

L. Peyrin-biroulet, C. Laclotte, and M. Bigard, Adalimumab maintenance therapy for Crohn???s disease with intolerance or lost response to infliximab: an open-label study, Alimentary Pharmacology & Therapeutics, vol.100, issue.Suppl., 2007.
DOI : 10.1136/gut.40.4.443

S. Prahalad and D. Glass, A comprehensive review of the genetics of juvenile idiopathic arthritis, Pediatric Rheumatology, vol.6, issue.1, p.16, 2008.
DOI : 10.1186/1546-0096-6-11

. Prescrire, Certolizumab pegol: new drug As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors, Prescrire Int, vol.18, issue.101, pp.108-110, 2009.

A. Ravelli and A. Martini, Juvenile idiopathic arthritis. The Lancet, 2007.

S. Raychaudhuri and E. Farber, The prevalence of psoriasis in the world, Journal of the European Academy of Dermatology and Venereology, vol.25, issue.4, pp.16-17, 2001.
DOI : 10.1111/j.1440-0960.1984.tb00618.x

A. Remy, J. Avouac, L. Gossec, and C. B. , Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and metaanalysis, Clin Exp Rheumatol, vol.29, issue.1, pp.96-103, 2011.

M. Roguska, J. Pedersen, C. Keddy, A. Henry, S. Searle et al., Humanization of murine monoclonal antibodies through variable domain resurfacing., Proceedings of the National Academy of Sciences, vol.91, issue.3, pp.969-973, 1994.
DOI : 10.1073/pnas.91.3.969

W. Sandborn, S. Hanauer, K. Seymour, M. Safdi, D. Wolf et al., Etanercept for active Crohn's disease: A randomized, double-blind, 2001.

W. Sandborn, B. Feagan, G. Radford-smith, A. Kovacs, R. Enns et al., CDP571, a humanised monoclonal antibody to tumour necrosis factor ??, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial, Gut, vol.53, issue.10, pp.53-1485, 2004.
DOI : 10.1136/gut.2003.035253

J. Sany, Polyarthrite rhumatoïde de l'adulte, conception actuelle, John Libbey Eurotext, p.298, 2003.

M. Schon and W. Boehncke, Psoriasis, New England Journal of Medicine, vol.352, issue.18, pp.1899-1912, 2005.
DOI : 10.1056/NEJMra041320

P. Seksik, Microbiote intestinal et MICI, Gastroent??rologie Clinique et Biologique, vol.34, issue.4, pp.48-55, 2010.
DOI : 10.1016/S0399-8320(10)70007-5

S. Setoguchi, D. Solomon, M. Weinblatt, J. Katz, J. Avorn et al., Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis, 2006.

D. Shealy, A. Cai, K. Staquet, A. Baker, E. Lacy et al., Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor ??, mAbs, vol.54, issue.4, 2010.
DOI : 10.1186/ar1028

S. Siberil, C. Dutertre, C. Boix, and J. Teillaud, Anticorps monoclonaux à usage thérapeutique : un peu d'histoire, 2005.

C. Siegel, S. Marden, S. Persing, R. Larson, and B. Sands, Risk of Lymphoma Associated With Combination Anti???Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis, Clinical Gastroenterology and Hepatology, vol.7, issue.8, pp.874-881, 2009.
DOI : 10.1016/j.cgh.2009.01.004

S. Wadsworth, D. Cavender, S. Beers, P. Lalan, P. Schaefer et al., RWJ- 67657, a potent, 1999.

R. Wallis, Tumour necrosis factor antagonists: structure, function, and tuberculosis risks, The Lancet Infectious Diseases, vol.8, issue.10, pp.601-611, 2008.
DOI : 10.1016/S1473-3099(08)70227-5

B. Weill and F. Batteux, Immunopathologie et réactions inflammatoires, p.310, 2003.

T. Winter, J. Wright, S. Ghosh, J. Jahnsen, A. Innes et al., Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study, Alimentary Pharmacology and Therapeutics, vol.13, issue.4, pp.11-12, 2004.
DOI : 10.1016/S0002-9270(02)05259-0

M. Wong, D. Ziring, Y. Korin, D. Sheetal, K. Sungjin et al., TNF?? blockade in human diseases: Mechanisms and future directions, Clinical Immunology, vol.126, issue.2, pp.121-136, 2008.
DOI : 10.1016/j.clim.2007.08.013

URL : http://europepmc.org/articles/pmc2291518?pdf=render

. Disponible-sur-<http, (page consultée en février 2013b) Notice HUMIRA®. Disponible sur <http://www.ema.europa.eu/docs/fr_FR/document_library/EPAR_- Product_Information/human/000481/WC500050870.pdf> ? ema.europa.eu (page consultée en mars 2013c). Notice SIMPONI®. Disponible sur <http Disponible sur <http

. Disponible-sur-<www and . Orpha, net/consor4.01/www/cgi- bin/Disease_Search.php?lng=FR&data_id=806&Disease_Disease_Search_diseaseGr oup=Takayasu> ? HAS-santé.fr (page consultée en janvier 2013a) Arthrite juvénile idiopathique

. Disponible-sur-<http, 09/ald_31_pnds_arthrite_juvenile_web.pdf> ? HAS-santé.fr (page consultée en février 2013b) Avis de la commission de transparence du 3 octobre 2012 concernant REMICADE®. Disponible sur <http, 2009.